Brokerages Set GSK plc (LON:GSK) Target Price at GBX 1,829.17

GSK plc (LON:GSK) has been assigned a consensus rating of “Hold” from the six research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is GBX 1,829.17.

Several research firms recently issued reports on GSK. Shore Capital reiterated a “buy” rating on shares of GSK in a report on Thursday, January 8th. Jefferies Financial Group restated a “buy” rating and set a GBX 2,100 target price on shares of GSK in a research report on Wednesday, January 7th. UBS Group reiterated a “neutral” rating and set a GBX 1,940 price target on shares of GSK in a research report on Friday. Berenberg Bank boosted their price target on shares of GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a research note on Monday, November 24th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of GSK from GBX 1,600 to GBX 1,675 and gave the company a “hold” rating in a report on Thursday, January 15th.

GSK Price Performance

Shares of LON:GSK opened at GBX 1,807.64 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. The firm has a market capitalization of £72.92 billion, a PE ratio of 13.59, a PEG ratio of 1.24 and a beta of 0.31. The business’s 50 day moving average is GBX 1,817.89 and its 200-day moving average is GBX 1,633.24. GSK has a 1-year low of GBX 1,242.50 and a 1-year high of GBX 1,909.73.

GSK (LON:GSK) last posted its quarterly earnings data on Wednesday, October 29th. The company reported GBX 55 earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Sell-side analysts predict that GSK will post 175.980975 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Wendy Becker purchased 441 shares of GSK stock in a transaction dated Friday, December 19th. The shares were acquired at an average cost of GBX 1,809 per share, for a total transaction of £7,977.69. Also, insider Jonathan Symonds acquired 1,650 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were bought at an average cost of GBX 1,810 per share, with a total value of £29,865. Corporate insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.